Montreal Classification for Inflammatory Bowel Disease (IBD)
Why Use
Provides a structured approach to describe the severity and characteristics of IBD. Facilitates communication among healthcare providers by using a standardized terminology. Aids in predicting disease progression and determining the need for aggressive management.
When to Use
Use during the initial diagnostic evaluation and follow-up of Crohn disease or ulcerative colitis to categorize patients into specific phenotypes and guide treatment planning. May be used in research or clinical trials to ensure standardized classification of patient populations.
Formula
Pearls / Pitfalls
The Montreal Classification is descriptive but does not incorporate newer insights into the molecular or immunologic underpinnings of inflammatory bowel disease (IBD). Reclassification may be needed as the disease evolves over time.
Advice
Use the classification results to tailor treatment options, such as immunomodulators, biologics, or surgery, based on disease severity and phenotype. Incorporate classification results into multidisciplinary discussions, including gastroenterologists and surgeons, to optimize patient care. Monitor disease progression and reassess the classification periodically, particularly in cases of changing clinical presentation or treatment failure. Do not use this tool as the sole determinant of management decisions; clinical context, patient history, specialist consultation, and other diagnostic tools are essential. For more detailed management recommendations, please refer to regional guidelines, such as those from the American Gastroenterological Association , American College of Gastroenterology , and American Society of Colon and Rectal Surgeons .